Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that abstracts related to trials of the company’s lead therapeutic, vofatamab, have been accepted for presentation at the upcoming 2019 American Society for Clinical Oncology (ASCO) Annual Meeting, which will take place May 31 to June 4, 2019 in Chicago, Illinois.
April 25, 2019
· 3 min read